MEDFORD, Mass., September 26, 2007 Nanobiosym Inc., announced today that it has been awarded a highly competitive $2 million contract from the United States Defense Threat Reduction Agency (DTRA), a branch of the US Department of Defense. The winners of this award were selected after an intense competition among many of the nations leading US academic, government, and industrial labs.
Nanobiosym, and its commercial partner Nanobiosym Diagnostics, have been privately developing Gene-RADAR, a portable nanotechnology-enabled platform, that can rapidly and accurately detect genetic fingerprints from any biological organism. The companys vision is to give patients worldwide real-time access to their own diagnostic information via low-cost handheld devices. Nanobiosym Diagnostics also seeks to leverage its nanotechnology platform to enable portable real-time detection of food and air-borne pathogens, as well as water testing, animal and crop testing, and screening of blood and transplant organs.
We are delighted that DTRA has recognized our unique proprietary technological platform with this award, said Dr. Anita Goel, M.D., PhD., Chairman and CEO of Nanobiosym. This is our first defense contract and is a major step towards establishing the US government as one of our long-term customers. Nanobiosym has been previously recognized by several other prominent awards, including multiple rounds of funding from the Defense Advance Research Project Agency (DARPA), the Air Force Office of Scientific Research (AFOSR), and the U.S. Department of Energy (DOE). Nanobiosym shares DTRAs strategic mission to reduce the threat of biological warfare and bioterrorism and during the course of the DTRA contract plans to validate the use of Nanobiosyms proprietary technology platform for emerging biodefense applications. In the coming years, we envision a significant paradigm shift in healthcare where the ability to diagnose disease is taken out of a pathology lab and broug
|Contact: NBS Media & Public Relations|
Feinstein Kean Healthcare